Literature DB >> 24755207

Benzodiazepine treatment can impair or spare extinction, depending on when it is given.

Genevra Hart1, Marios C Panayi2, Justin A Harris3, R Frederick Westbrook4.   

Abstract

BACKGROUND: Benzodiazepines reduce the effectiveness of fear extinction in rodents and of exposure therapy in people suffering from anxiety disorders if given concomitantly with the behavioral treatment from its onset. The present experiments used rats to examine whether benzodiazepines had the same detrimental effect when given after some initial extinction had been conducted drug-free.
METHODS: Rats were trained to fear a context (Experiments 1 and 2) or discrete cue (Experiment 3) and were extinguished to the context or cue under a benzodiazepine (midazolam) or vehicle. Extinction occurred either continuously in one session, with the drug or vehicle administered prior to the onset, or divided into two sessions, with the drug or vehicle administered prior to the second session. Rats were then tested, drug-free, for fear of the context or CS.
RESULTS: Midazolam disrupted context and cue extinction when administered prior to the initial session but failed to disrupt extinction when given prior to the second session.
CONCLUSIONS: The results in an animal model confirm that the effectiveness of extinction can be reduced when combined with benzodiazepines. They also suggest that the effectiveness of extinction will not be reduced when combined with a benzodiazepine if the patient has undergone some initial extinction drug-free.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Benzodiazepine; Extinction; Midazolam; Pavlovian conditioning; Re-extinction

Mesh:

Substances:

Year:  2014        PMID: 24755207     DOI: 10.1016/j.brat.2014.02.004

Source DB:  PubMed          Journal:  Behav Res Ther        ISSN: 0005-7967


  7 in total

Review 1.  Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders.

Authors:  N Singewald; C Schmuckermair; N Whittle; A Holmes; K J Ressler
Journal:  Pharmacol Ther       Date:  2014-12-27       Impact factor: 12.310

2.  Pharmacotherapy for Anxiety Disorders: From First-Line Options to Treatment Resistance.

Authors:  Andrew J Melaragno
Journal:  Focus (Am Psychiatr Publ)       Date:  2021-06-17

3.  Skin conductance levels and responses in Asian and White participants during fear conditioning.

Authors:  Alexandra K Gold; M Alexandra Kredlow; Scott P Orr; Catherine A Hartley; Michael W Otto
Journal:  Physiol Behav       Date:  2022-04-06

4.  Contemporary treatment of anxiety in primary care: a systematic review and meta-analysis of outcomes in countries with universal healthcare.

Authors:  Erin L Parker; Michelle Banfield; Daniel B Fassnacht; Timothy Hatfield; Michael Kyrios
Journal:  BMC Fam Pract       Date:  2021-05-15       Impact factor: 2.497

5.  Benzodiazepine administration prevents the use of error-correction mechanisms during fear extinction.

Authors:  Genevra Hart; Nathan M Holmes; Justin A Harris; R Frederick Westbrook
Journal:  Learn Behav       Date:  2014-12       Impact factor: 1.926

6.  Combined Neuropeptide S and D-Cycloserine Augmentation Prevents the Return of Fear in Extinction-Impaired Rodents: Advantage of Dual versus Single Drug Approaches.

Authors:  Simone B Sartori; Verena Maurer; Conor Murphy; Claudia Schmuckermair; Patrick Muigg; Inga D Neumann; Nigel Whittle; Nicolas Singewald
Journal:  Int J Neuropsychopharmacol       Date:  2016-06-01       Impact factor: 5.176

7.  Effects of Alcohol and Cocaine in a Mutant Mouse Model of Predisposition to Post-Traumatic Stress Disorder.

Authors:  Eleni Paizanis; Michela Crotti; Anthony Petit; Mathilde Règue; Virginie Beray-Berthat; Florence Noble; Laurence Lanfumey; Raymond Mongeau
Journal:  Front Pharmacol       Date:  2020-05-08       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.